The Latest Breaking News from ADMA

ADMA stock rocketed Monday after the Food and Drug Administration approved its new immunoglobulin production process.

Futures rose as President Trump said China tariffs will fall "substantially" and won't fire Fed chief Powell. Stocks boomed Tuesday on Treasury Secretary Scott Bessent. Tesla earnings fell with Elon Musk bullish.

ADMA stock hit a new buy point in recent weeks after recovering from an unexpected plunge that sent shares below a key level.

ADMA stock rocketed Friday after the biotech company inked a deal with KPMG as its new independent registered public accounting firm.

ADMA stock plummeted Thursday after the company's auditor unexpectedly resigned. But ADMA Biologics kept its guidance for this year and next.

If you're like most investors — you assume AI giant Nvidia is the best stock of the year. But 2024's major champ isn't even in the S&P 500.

ADMA Biologics Inc (NASDAQ: ADMA) shares are trading higher Monday after the company announced it received U.S. Food and Drug Administration approval for its sixth plasma collection center.

Benzinga Pro data, ADMA Biologics (NASDAQ:ADMA) reported Q1 sales of $29.10 million. Earnings fell to a loss of $25.01 million, resulting in a 50.2% decrease from last quarter.

ADMA Biologics (NASDAQ:ADMA) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings ADMA Biologics missed estimated earnings by 25.0%, reporting an EPS of $-0.1 versus an estimate of $-0.08.